Abstract | BACKGROUND: PATIENTS AND METHODS: Fifty-six previously treated advanced NSCLC patients received BMS-184476 at a dose of 60 mg/m(2) administered intravenously over 1 h every 21 days. RESULTS: The median number of cycles delivered per patient was five (range one to 17). Dose reduction was required in only 3.8% of cycles. Grade 4 neutropenia occurred in 19.6% of patients, but no grade 4 thrombocytopenia or anemia was reported. Febrile neutropenia was observed in only two (3.6%) patients and there were no life-threatening events. Grade 3/4 peripheral sensory-motor neuropathy was reported in 9% of patients. Other non-hematological toxicities, such as nausea and vomiting, myalgia and arthralgia, diarrhea, and mucositis, were uncommon. Partial responses were observed in eight (14.3%) patients and stable disease in 33 (58.9%). Median progression-free survival was 3.7 months [95% confidence interval (CI) 2.7-5.4] and median overall survival was 10 months (95% CI 6-13.4). CONCLUSIONS:
BMS-184476 was well tolerated at the dose of 60 mg/m(2) and showed evidence of antitumor activity in previously treated NSCLC.
|
Authors | C Camps, E Felip, J M Sanchez, B Massuti, A Artal, L Paz-Ares, A Carrato, V Alberola, A Blasco, J Baselga, L Astier, M Voi, R Rosell, Spanish Lung Cancer Group |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 16
Issue 4
Pg. 597-601
(Apr 2005)
ISSN: 0923-7534 [Print] England |
PMID | 15684226
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Comparative Study, Journal Article)
|
Chemical References |
- Taxoids
- 7-methylthiomethylpaclitaxel
|
Topics |
- Adult
- Aged
- Carcinoma, Non-Small-Cell Lung
(blood, drug therapy)
- Female
- Gastrointestinal Diseases
(chemically induced)
- Humans
- Lung Neoplasms
(blood, drug therapy)
- Male
- Middle Aged
- Survival Analysis
- Taxoids
(adverse effects, therapeutic use)
|